Pacira BioSciences (PCRX) Current Leases (2019 - 2026)

Pacira BioSciences' Current Leases history runs 8 years deep, the most recent figure standing at $9.8 million for Q1 2026.

• In Q1 2026, Current Leases rose 4.39% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (up 4.39% YoY), while the FY2025 annual figure was $9.8 million, up 10.71% from the prior year.
• Current Leases was $9.8 million for Q1 2026 at Pacira BioSciences, roughly flat from $9.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $9.8 million in Q4 2025 to a low of $8.0 million in Q1 2022.
• Historically, Current Leases has averaged $9.0 million across 5 years, with a median of $9.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Current Leases soared 45.7% in 2022, then retreated 3.51% in 2023.
• A 5-year view of Current Leases shows it stood at $9.1 million in 2022, then fell by 3.51% to $8.8 million in 2023, then advanced by 0.98% to $8.9 million in 2024, then rose by 10.71% to $9.8 million in 2025, then slipped by 0.21% to $9.8 million in 2026.
• The last three Current Leases figures came in at $9.8 million (Q1 2026), $9.8 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.